Cardio-oncology is a medical specialty focused on protecting the heart before, during, and after cancer treatment. It exists because many cancer therapies, while effective at fighting tumors, can damage the cardiovascular system. The field brings cardiologists and oncologists together to manage that tension: treating cancer aggressively while minimizing harm to the heart.
Why Cancer Treatment Threatens the Heart
Dozens of cancer therapies can injure the heart, blood vessels, or both. The damage ranges from subtle changes detectable only on imaging to full-blown heart failure. Certain drug classes carry especially well-known risks.
Anthracyclines, a widely used group of chemotherapy drugs, cause damage primarily by generating unstable molecules called free radicals inside heart muscle cells. These free radicals overwhelm the cell’s defenses, disrupt its energy-producing structures (mitochondria), and trigger cell death pathways. Over time, anthracyclines also reduce the heart’s population of repair cells, making recovery harder. The damage tends to be cumulative and dose-dependent, meaning higher lifetime exposure raises risk significantly. It can also be permanent.
Targeted therapies that block a protein called HER2 work differently. They interfere with a signaling pathway that heart cells also rely on for maintenance and survival. Unlike anthracycline damage, this type of injury is often reversible once the drug is stopped, though it can still cause serious problems during treatment.
Newer immunotherapies, including immune checkpoint inhibitors, carry a distinct risk: inflammation of the heart muscle (myocarditis). This occurs in roughly 1% of patients, but it’s the deadliest immune-related side effect of these drugs, with early reports putting mortality as high as 50%. The inflammation can trigger dangerous heart rhythms, including sustained rapid heartbeats originating in the lower chambers of the heart. Radiation therapy to the chest adds yet another layer of risk, potentially causing scarring of the heart lining, coronary artery disease, and rhythm disturbances.
What a Cardio-Oncologist Actually Does
The field follows a structured five-step approach laid out in guidelines from the European Society of Cardiology. It starts before cancer treatment even begins.
First, a baseline cardiovascular risk assessment identifies patients who are already vulnerable. Pre-existing high blood pressure, coronary artery disease, valve problems, or even borderline heart function all raise the chance that cancer therapy will cause cardiac complications. Patients with these risk factors get closer monitoring and sometimes preventive medications.
Second, surveillance continues throughout treatment. For patients receiving HER2-targeted therapy, for example, guidelines recommend heart imaging at baseline and then every three months during the first year of treatment, with blood tests to detect early signs of heart muscle injury. The monitoring schedule intensifies for higher-risk patients.
Third, if heart problems develop during treatment, the cardio-oncology team manages them while trying to keep cancer therapy on track. This is the core balancing act of the field. Treatment interruption guidelines are specific: HER2-targeted therapy should be paused if the heart’s pumping function drops below 40% or if a patient develops significant symptoms, but it can continue with added heart medications if pumping function stays at 40% or above without symptoms.
Fourth, patients undergo a cardiovascular assessment at the end of cancer treatment to establish a new baseline. Fifth, high-risk survivors enter long-term follow-up programs, sometimes for years or decades. This applies to both adults and childhood cancer survivors.
How Heart Damage Gets Detected
The challenge with cancer-related heart damage is that it often starts silently. A patient may feel perfectly fine while their heart function is already declining. Standard imaging measures the heart’s ejection fraction, which represents the percentage of blood pumped out with each beat. Cardiotoxicity is most commonly defined as a drop of more than 10 percentage points to below the normal range.
But ejection fraction is a relatively blunt tool. A more sensitive measurement called global longitudinal strain (GLS) can pick up early dysfunction before the ejection fraction drops noticeably. In one illustrative example, GLS shifted dramatically (from -20.7% to -16.1%) after anthracycline treatment, while ejection fraction barely changed (60% to 55%). A relative change in GLS greater than 15% is considered clinically meaningful, and it often triggers closer monitoring or a change in treatment strategy.
Blood tests add another layer of detection. Troponin, a protein released when heart cells are injured, can rise during chemotherapy and predicts later heart problems. Another marker tied to heart wall stress can also signal trouble, though only a sustained elevation (not a temporary spike) reliably predicts progression to heart failure.
Symptoms Patients Should Recognize
Because monitoring catches many cases early, some patients never develop noticeable symptoms. When symptoms do appear, they typically mirror those of heart failure: increasing shortness of breath, unusual fatigue, swelling in the legs or ankles, and reduced exercise tolerance. Some targeted therapies are well known for causing decreased exercise tolerance even without overt heart failure.
Chest pain during certain chemotherapy regimens can signal coronary artery spasm, a distinct type of toxicity where blood vessels temporarily clamp down and reduce blood flow to the heart. With immunotherapy, symptoms of myocarditis may include chest pain, palpitations, dizziness, or sudden difficulty breathing. Any new cardiovascular symptoms during cancer treatment warrant prompt evaluation rather than waiting for the next scheduled check.
Preventing Heart Damage During Treatment
Prevention in cardio-oncology is an active area with mixed results so far. The European Society of Cardiology gives a moderate recommendation for statins in patients at high or very high risk of treatment-related heart damage, but clinical trials have produced conflicting evidence. One large trial (STOP-CA) found that patients taking a statin had significantly lower rates of cardiac dysfunction than those on placebo (9% vs. 22%). Two other trials of similar design found no benefit. The differences may partly reflect the use of other heart-protective medications like beta-blockers in some trial populations, which could have masked the statin’s effect.
Beyond medications, the broader preventive strategy includes choosing the least cardiotoxic treatment regimen when oncologically appropriate, limiting cumulative drug doses, and intensifying monitoring for patients with pre-existing risk factors. Exercise programs during and after cancer treatment have also gained traction as a way to support cardiovascular resilience, though the specifics vary by patient.
Why Survivorship Matters So Much
The long-term significance of cardio-oncology becomes clear in survivorship data. A study of over 104,000 adults diagnosed with nine common cancers found that cardiovascular death eventually overtakes cancer death for many survivors, particularly those diagnosed at older ages.
Among survivors diagnosed at age 80 or older, cardiovascular mortality surpassed cancer mortality for all nine cancer types studied, sometimes within just a few years. For melanoma survivors in this age group, the crossover happened at 1.9 years. For breast cancer, 7.1 years. For those diagnosed between ages 60 and 79, the crossover still occurred for most cancer types, though it took longer: 4.8 years for bladder cancer, 12.7 years for breast cancer. Among those diagnosed between 40 and 59, cardiovascular mortality remained low and only overtook cancer mortality for uterine cancer, after 11 years.
These numbers underscore why cardio-oncology extends well beyond the treatment phase. For many cancer survivors, especially those treated at older ages or with pre-existing heart risk factors, cardiovascular disease becomes a greater long-term threat than cancer recurrence. Managing that risk requires the kind of sustained, coordinated care that defines the field.